Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real-world setting: The XENSOR Study.

Gorgojo-Martínez JJ, Basagoiti-Carreño B, Sanz-Velasco A, Serrano-Moreno C, Almodóvar-Ruiz F

International journal of clinical practice19 Aug 2019Cited by 52 (Europe PMC)

PMID31397946DOI10.1111/ijcp.13399PepBankPUB-31397946

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanObservational studyEfficacy outcome
In adults with obesity treated in routine care, weight loss with liraglutide (-7.7 kg) was significantly greater than with orlistat (-3.3 kg).
In plain wordsIn adults with obesity treated in routine care, liraglutide led to more weight loss than orlistat.
Peptide
Liraglutide
Outcome
DecreaseWeight loss versus orlistat
Study
n = 500
Comparator
Orlistat 120 mg three times a day
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
up to 3 mg dailyAs given in this study (human).
Measurements
Weight change
−7.7 kg
liraglutide
Weight change
−3.3 kg
orlistat
Source sentences
Summary
WL with liraglutide (-7.7 kg) was significantly greater than that observed with orlistat (-3.3 kg)
3 context sentences(design, population, supporting numbers)
Summary · context
Retrospective, observational cohort study comparing clinical outcomes of orlistat 120 mg three times a day and liraglutide (up to 3 mg daily) in adult patients with BMI ≥30 kg/m² or ≥27 kg/m² with at least a weight-related comorbidity who had failed to lose at least 5% of their…
Summary · context
The co-primary end-points, assessed at 3-6 months and at the end of the follow-up, were weight change from baseline, proportion of patients who lost at least 5% of their baseline weight and adjusted differences in WL between both drugs.
Summary · context
Five hundred patients, 400 in the group of orlistat (age 47.0, weight 107.8 kg) and 100 in the group of liraglutide (age 51.9 years, weight 105.1 kg), were included.
Report a problemFND-3139794606
02HumanObservational studyEfficacy outcome
In adults with obesity treated in routine care, more people lost at least 5% of baseline weight with liraglutide (64.7%) than with orlistat (27.4%).
In plain wordsIn adults with obesity treated in routine care, more people lost at least 5% of their weight with liraglutide than with orlistat.
Peptide
Liraglutide
Outcome
IncreaseProportion losing at least 5% of baseline weight
Study
n = 500
Comparator
Orlistat 120 mg three times a day
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
up to 3 mg dailyAs given in this study (human).
Measurements
Proportion with weight loss of at least 5%
64.7%
liraglutide
Proportion with weight loss of at least 5%
27.4%
orlistat
Source sentences
Summary
more individuals lost at least 5% of their baseline weight with liraglutide (64.7%) than with orlistat (27.4%)
3 context sentences(design, population, supporting numbers)
Summary · context
Retrospective, observational cohort study comparing clinical outcomes of orlistat 120 mg three times a day and liraglutide (up to 3 mg daily) in adult patients with BMI ≥30 kg/m² or ≥27 kg/m² with at least a weight-related comorbidity who had failed to lose at least 5% of their…
Summary · context
The co-primary end-points, assessed at 3-6 months and at the end of the follow-up, were weight change from baseline, proportion of patients who lost at least 5% of their baseline weight and adjusted differences in WL between both drugs.
Summary · context
Five hundred patients, 400 in the group of orlistat (age 47.0, weight 107.8 kg) and 100 in the group of liraglutide (age 51.9 years, weight 105.1 kg), were included.
Report a problemFND-3139794607
03HumanObservational studyEfficacy outcome
In adults with obesity treated in routine care, liraglutide significantly reduced body weight over a median follow-up of 7 months.
In plain wordsIn adults with obesity treated in routine care, liraglutide lowered body weight over about 7 months.
Peptide
Liraglutide
Outcome
DecreaseBody weight change from baseline
Study
n = 100
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
up to 3 mg daily · median follow-up 7 monthsAs given in this study (human).
Source sentences
Summary
Treatment with both drugs significantly reduced weight, fasting plasma glucose, systolic BP, low-density lipoprotein-cholesterol and alanine transaminase
3 context sentences(design, population, supporting numbers)
Summary · context
Retrospective, observational cohort study comparing clinical outcomes of orlistat 120 mg three times a day and liraglutide (up to 3 mg daily) in adult patients with BMI ≥30 kg/m² or ≥27 kg/m² with at least a weight-related comorbidity who had failed to lose at least 5% of their…
Summary · context
The co-primary end-points, assessed at 3-6 months and at the end of the follow-up, were weight change from baseline, proportion of patients who lost at least 5% of their baseline weight and adjusted differences in WL between both drugs.
Summary · context
Five hundred patients, 400 in the group of orlistat (age 47.0, weight 107.8 kg) and 100 in the group of liraglutide (age 51.9 years, weight 105.1 kg), were included.
Report a problemFND-3139794601
04HumanObservational studyEfficacy outcome
In adults with obesity treated in routine care, the rate of prediabetes decreased significantly more with liraglutide than with orlistat.
In plain wordsIn adults with obesity treated in routine care, fewer people had prediabetes after liraglutide than after orlistat.
Peptide
Liraglutide
Outcome
DecreaseRate of prediabetes
Study
n = 500
Comparator
Orlistat 120 mg three times a day
Outcome group
Glycemic control · Metabolic and weight
Studied dose
up to 3 mg dailyAs given in this study (human).
Source sentences
Summary
Rates of prediabetes significantly decreased with liraglutide in comparison to orlistat.
3 context sentences(design, population, supporting numbers)
Summary · context
Retrospective, observational cohort study comparing clinical outcomes of orlistat 120 mg three times a day and liraglutide (up to 3 mg daily) in adult patients with BMI ≥30 kg/m² or ≥27 kg/m² with at least a weight-related comorbidity who had failed to lose at least 5% of their…
Summary · context
The co-primary end-points, assessed at 3-6 months and at the end of the follow-up, were weight change from baseline, proportion of patients who lost at least 5% of their baseline weight and adjusted differences in WL between both drugs.
Summary · context
Five hundred patients, 400 in the group of orlistat (age 47.0, weight 107.8 kg) and 100 in the group of liraglutide (age 51.9 years, weight 105.1 kg), were included.
Report a problemFND-3139794608
05HumanObservational studyEfficacy outcome
In adults with obesity treated in routine care, liraglutide significantly reduced fasting plasma glucose over a median follow-up of 7 months.
In plain wordsIn adults with obesity treated in routine care, liraglutide lowered fasting blood glucose over about 7 months.
Peptide
Liraglutide
Outcome
DecreaseFasting plasma glucose change
Study
n = 100
Outcome group
Glycemic control · Metabolic and weight
Studied dose
up to 3 mg daily · median follow-up 7 monthsAs given in this study (human).
Source sentences
Summary
Treatment with both drugs significantly reduced weight, fasting plasma glucose, systolic BP, low-density lipoprotein-cholesterol and alanine transaminase
3 context sentences(design, population, supporting numbers)
Summary · context
Retrospective, observational cohort study comparing clinical outcomes of orlistat 120 mg three times a day and liraglutide (up to 3 mg daily) in adult patients with BMI ≥30 kg/m² or ≥27 kg/m² with at least a weight-related comorbidity who had failed to lose at least 5% of their…
Summary · context
The co-primary end-points, assessed at 3-6 months and at the end of the follow-up, were weight change from baseline, proportion of patients who lost at least 5% of their baseline weight and adjusted differences in WL between both drugs.
Summary · context
Five hundred patients, 400 in the group of orlistat (age 47.0, weight 107.8 kg) and 100 in the group of liraglutide (age 51.9 years, weight 105.1 kg), were included.
Report a problemFND-3139794602
06HumanObservational studyEfficacy outcome
In adults with obesity treated in routine care, liraglutide significantly reduced systolic blood pressure over a median follow-up of 7 months.
In plain wordsIn adults with obesity treated in routine care, liraglutide lowered systolic blood pressure over about 7 months.
Peptide
Liraglutide
Outcome
DecreaseSystolic blood pressure change
Study
n = 100
Outcome group
Blood pressure · Cardiovascular
Studied dose
up to 3 mg daily · median follow-up 7 monthsAs given in this study (human).
Source sentences
Summary
Treatment with both drugs significantly reduced weight, fasting plasma glucose, systolic BP, low-density lipoprotein-cholesterol and alanine transaminase
3 context sentences(design, population, supporting numbers)
Summary · context
Retrospective, observational cohort study comparing clinical outcomes of orlistat 120 mg three times a day and liraglutide (up to 3 mg daily) in adult patients with BMI ≥30 kg/m² or ≥27 kg/m² with at least a weight-related comorbidity who had failed to lose at least 5% of their…
Summary · context
The co-primary end-points, assessed at 3-6 months and at the end of the follow-up, were weight change from baseline, proportion of patients who lost at least 5% of their baseline weight and adjusted differences in WL between both drugs.
Summary · context
Five hundred patients, 400 in the group of orlistat (age 47.0, weight 107.8 kg) and 100 in the group of liraglutide (age 51.9 years, weight 105.1 kg), were included.
Report a problemFND-3139794603
07HumanObservational studyEfficacy outcome
In adults with obesity treated in routine care, liraglutide significantly reduced low-density lipoprotein-cholesterol over a median follow-up of 7 months.
In plain wordsIn adults with obesity treated in routine care, liraglutide lowered LDL cholesterol over about 7 months.
Peptide
Liraglutide
Outcome
DecreaseLDL-cholesterol change
Study
n = 100
Outcome group
Lipids · Cardiovascular
Studied dose
up to 3 mg daily · median follow-up 7 monthsAs given in this study (human).
Source sentences
Summary
Treatment with both drugs significantly reduced weight, fasting plasma glucose, systolic BP, low-density lipoprotein-cholesterol and alanine transaminase
3 context sentences(design, population, supporting numbers)
Summary · context
Retrospective, observational cohort study comparing clinical outcomes of orlistat 120 mg three times a day and liraglutide (up to 3 mg daily) in adult patients with BMI ≥30 kg/m² or ≥27 kg/m² with at least a weight-related comorbidity who had failed to lose at least 5% of their…
Summary · context
The co-primary end-points, assessed at 3-6 months and at the end of the follow-up, were weight change from baseline, proportion of patients who lost at least 5% of their baseline weight and adjusted differences in WL between both drugs.
Summary · context
Five hundred patients, 400 in the group of orlistat (age 47.0, weight 107.8 kg) and 100 in the group of liraglutide (age 51.9 years, weight 105.1 kg), were included.
Report a problemFND-3139794604
08HumanObservational studyEfficacy outcome
In adults with obesity treated in routine care, liraglutide significantly reduced alanine transaminase over a median follow-up of 7 months.
In plain wordsIn adults with obesity treated in routine care, liraglutide lowered the liver enzyme ALT over about 7 months.
Peptide
Liraglutide
Outcome
DecreaseAlanine transaminase change
Study
n = 100
Outcome group
Liver fat and liver function · Liver
Studied dose
up to 3 mg daily · median follow-up 7 monthsAs given in this study (human).
Source sentences
Summary
Treatment with both drugs significantly reduced weight, fasting plasma glucose, systolic BP, low-density lipoprotein-cholesterol and alanine transaminase
3 context sentences(design, population, supporting numbers)
Summary · context
Retrospective, observational cohort study comparing clinical outcomes of orlistat 120 mg three times a day and liraglutide (up to 3 mg daily) in adult patients with BMI ≥30 kg/m² or ≥27 kg/m² with at least a weight-related comorbidity who had failed to lose at least 5% of their…
Summary · context
The co-primary end-points, assessed at 3-6 months and at the end of the follow-up, were weight change from baseline, proportion of patients who lost at least 5% of their baseline weight and adjusted differences in WL between both drugs.
Summary · context
Five hundred patients, 400 in the group of orlistat (age 47.0, weight 107.8 kg) and 100 in the group of liraglutide (age 51.9 years, weight 105.1 kg), were included.
Report a problemFND-3139794605

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.